Skip to search formSkip to main contentSkip to account menu

Caspofungin

Known as: (4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide, (4R,5S)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (1->6) disulfide, 1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0 
The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis… 
National Institutes of Health

Related topics

Related topics

19 relations

Broader (3)

Antifungal AgentsEchinocandinsLipopeptides
AspergillosisCaspofungin acetate 50 MG InjectionCaspofungin acetate 70 MG Injection [Cancidas]Caspofungin:MCnc:Pt:Ser/Plas:Qn

Narrower (4)

CancidasCaspofungin acetateL 743,872MK 0991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility.
Review
2010
Review
2010
Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital.
Mucormycosis is an angio-invasive mycosis with high morbidity and mortality rates which mainly affects immunocompromised patients… 
Highly Cited
2009
Highly Cited
2009
Phaeohyphomycosis due to Alternaria species in transplant recipients
R.D. Boyce, P.J. Deziel, C.C. Otley, M.P. Wilhelm, A.J. Eid, N.L. Wengenack, R.R. Razonable. Phaeohyphomycosis due to Alternaria… 
2008
2008
Fungal infections after haematology unit renovation: evidence of clinical, environmental and economical impact
Objective and methods:  The Haemato‐Oncology Unit, Hospital S. Joao, suffered extensive refurbishing intervention in order to… 
Highly Cited
2007
Highly Cited
2007
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK
Objective:  To evaluate the cost‐effectiveness of caspofungin vs. liposomal amphotericin B in the treatment of suspected fungal… 
Review
2006
Review
2006
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients
Neutropenia is an indicator of poor prognosis in patients with fungal infections. All available clinical trial experience from… 
Highly Cited
2006
Highly Cited
2006
Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species
ABSTRACT The minimum effective concentration (MEC) used to assess the in vitro antifungal activity of caspofungin against… 
Highly Cited
2006
Highly Cited
2006
Characterizing the Effects of Caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments
ABSTRACT We measured time-kills and postantifungal effects (PAFEs) of caspofungin against Candida albicans, C. parapsilosis, and… 
2004
2004
Refractory Candidal Meningitis in an Immunocompromised Patient Cured by Caspofungin
ABSTRACT Candidal meningitis is a rare infectious disease that usually leads to substantial morbidity and mortality. We present a… 
Review
2002
Review
2002
The first echinocandin: caspofungin
Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)